Patents of pharmaceutical products provide a limited term of protection and prevent the generic companies to access the patented drugs without authorization. However, this monopoly should not prevent the reasonable access to the patented products and to address the health issues of the public. The exception to this monopoly is provided by the ‘Compulsory License’ under the Patent Act, which allows the generic manufacturers to use or manufacture the patented drug upon fulfillment of certain conditions.
For more: http://www.origiin.com/2019/01/31/compulsory-license-a-lifeline-from-patent-to-patient/
IP Valuation 